MGD019 Trial for Advanced Cervical Cancer Shows Potential for Immunotherapy
The TRACTION trial is investigating the efficacy of MGD019 in controlling advanced cervical cancer in treatment-naive patients.
Asset / Drug
Drug and asset intelligence for MGD019 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Immunotherapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.